Role of the receptor for advanced glycation end products in hepatic fibrosis

Table 1 Expression of RAGE and ECM-related genes in rats cirrhotic due to BDL and TAA treatment

	Control	BDL	TAA
RAGE	1.00 ± 0.31	3.89 ± 0.92b	1.44 ± 0.47
α-SMA	1.00 ± 0.49	5.60 ± 1.59a	10.39 ± 6.78
Procollagen-α1(I)	1.00 ± 0.99	26.45 ± 3.37d	21.92 ± 8.48
MMP-13	1.00 ± 0.38	3.68 ± 2.50	52.88 ± 25.34a
TIMP-1	1.00 ± 0.46	6.50 ± 1.55b	25.47 ± 15.02

RAGE, α-SMA, procollagen-α1(I), MMP-13, and TIMP-1 transcript levels relative to β2-microglobulin ± SD of four animals per group. Data are expressed as n-fold increase compared to sham-operated and normal rats, respectively.

^aP < 0.05,

^bP < 0.01,

^dP < 0.001 vs normal controls. RAGE: Receptor for advanced glycation end products; ECM: Extracellular matrix; BDL: Bile duct ligation; TAA: Thioacetamide; SMA: Smooth muscle actin; MMP: Matrix metalloproteinase; TIMP: Tissue inhibitor of metalloproteinase.